Clinical Research Atlanta — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$301,473	50
2024	Research	$419,891	76
2023	Research	$907,919	62
2022	Research	$4,339,939	216
2021	Research	$2,056,773	83
2020	Research	$10,339	8
2019	Research	$122,558	24

Breakdown

Who paid Research payments · program years 2019–2025

Moderna TX, Inc. $6,776,649 362 payments
Merck Sharp & Dohme Corporation $591,034 5 payments
Eli Lilly and Company $368,337 23 payments
AstraZeneca Pharmaceuticals LP $136,660 2 payments
Pfizer Inc. $127,488 110 payments
Novartis Pharmaceuticals Corporation $104,688 2 payments
GlaxoSmithKline, LLC. $54,037 15 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $5,777,828 267 payments
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $673,430 12 payments
A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $591,034 5 payments
A Phase 3, Partly Randomized, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults $142,844 23 payments
A Phase 2, Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of Ly3549492 Compared With Placebo in Adult Participants 55 to 80 Years of Age and Bmi Within 22 to 25 Kg/M2 $137,640 1 payment
A Phase 4 Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety of 1 New $114,660 1 payment
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $104,688 2 payments
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $70,993 21 payments
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (Achieve-3) $61,907 5 payments
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults $55,187 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.